Filing identity and reporting period
Important identity discrepancy: The supplied filing is Stellar Biotechnologies, Inc.’s Form 10-K for the fiscal year ended September 30, 2015, not an Edesa Biotech, Inc. filing. The summary below reflects the filing text provided and should not be attributed to Edesa.
Stellar develops and manufactures Keyhole Limpet Hemocyanin (KLH) for pharmaceutical, research, and diagnostic uses. The company changed its fiscal year-end from August 31 to September 30, creating a one-month transition period in 2014. Fiscal 2015 is a 12-month period; the prior fiscal-year comparison is also 12 months but ended August 31, 2014.
Financial performance and position
| Metric | FY2015 | Prior comparable period |
|---|---|---|
| Revenue | $758,689 | $372,132 |
| Product sales | $563,689 | $143,553 |
| Contract services revenue | $195,000 | $192,000 |
| Grant revenue | $0 | $36,579 |
| Net loss | $2,843,029 | $8,439,523 |
| Operating cash used | $4,412,395 | $4,266,707 |
| Cash and cash equivalents at period end | $3,955,503 | $8,423,089 |
| Short-term investments at period end | $5,015,171 | $5,462,413 |
| Total assets at period end | $10,385,927 | $14,473,962 |
| Total liabilities at period end | $2,380,648 | $6,773,329 |
For the September 2015 quarter, revenue was $200,000 and net loss was $1.538 million; the filing’s quarterly table reports $119,000 revenue and a $4.635 million net loss for the quarter ended August 31, 2014. The periods are not identical quarter-end dates.
FY2015 expenses were $5.097 million, including $580,824 of costs of sales and contract services, $259,423 of aquaculture costs, $1.029 million of research and development, and $3.228 million of general and administrative costs. A standalone overall operating margin is not clearly presented; reported cost categories include aquaculture and other expenses outside costs of sales.
Working capital was $7.486 million, including cash and short-term investments of $8.971 million. The current-liability total includes a $1.551 million warrant liability that the filing says is noncash. The company reported no conventional long-term debt; the principal reported liability was the fair-value warrant liability. Capital expenditures were $274,589.
Changes and drivers
- Revenue rose about 104% year over year, driven by higher product sales, more customers, increased volume, and supply-agreement and custom-manufacturing activity. Contract services revenue was nearly flat, and NSF grant revenue ended.
- Net loss narrowed by about $5.6 million. Management attributed the improvement chiefly to a $2.131 million noncash gain from remeasuring warrant liabilities, increased sales, and lower R&D spending. The prior year included a $2.533 million warrant-liability loss.
- R&D expense fell from $2.459 million to $1.029 million as the company shifted resources from internal research and process development toward manufacturing in response to customer demand. General and administrative expense increased to $3.228 million, including higher legal, audit, Nasdaq-listing, business-development, and investor-relations costs.
- Operating cash use increased to $4.412 million. Cash and cash equivalents declined by $4.468 million year over year, while short-term investments also declined. The company began recording broader work-in-process and finished-goods inventory; inventory reached $557,280.
Outlook, risks, and notable items
- Management estimated approximately $5.5 million of funding needs for the next 12 months and believed available resources would fund planned operations for at least that period. It also expected ongoing losses and said additional financing might be needed; no new financing commitment was secured.
- Current limpet inventory was described as supporting annual KLH-intermediate capacity of at least 1,500 grams, with a projected maximum of 2,000 grams. Management cited a potential capacity of up to 20 kilograms in five to seven years, conditional on sufficient funding and successful expansion.
- The July 2015 Ostiones collaboration and related Baja California land lease support site-suitability work over three years. The site was not yet established for production; development involves funding, permitting, operational, political, and security risks.
- Revenue depends substantially on third-party development and regulatory success. KLH had not yet been used in a marketed commercial product, and product demand is variable. FY2015 product and contract-services revenue was concentrated: 85% came from five customers; two customers accounted for 91% of receivables.
- Operations were concentrated at the coastal Port Hueneme facility, with no backup site. The company also cited supply, contractor, customer-concentration, intellectual-property, competition, regulatory, foreign-exchange, and key-personnel risks.
- FY2015 included a $653,333 foreign-exchange loss, largely associated with Canadian-dollar cash exposure. Management estimated that a 10% annual currency-rate change would affect net loss by approximately $334,000. The company did not hedge this exposure.
- The company completed a 1-for-10 reverse split on September 2, 2015; common shares began Nasdaq trading on November 5, 2015. At September 30, 2015, 7,984,758 shares were outstanding; the filing reports 8,424,758 as of December 1, 2015.
- The company reported effective disclosure controls and internal control over financial reporting as of September 30, 2015. The external auditor did not attest to internal-control effectiveness because the company qualified as an emerging growth company.
Investor verification priorities
- Confirm the intended issuer: the source document identifies Stellar Biotechnologies, Inc., not Edesa Biotech, Inc.
- Review the audited statements and notes for cash runway, quarterly cash burn, warrant-liability valuation, and the effect of noncash warrant gains on reported earnings.
- Assess customer concentration, supply-agreement volumes and terms, and the clinical and regulatory status of customer programs that drive KLH demand.
- Verify production capacity, inventory realizability, contractor dependence, and the funding and milestones required for the proposed Mexico expansion.
- Check subsequent warrant exercises, dilution and share counts, and ongoing Nasdaq listing compliance.
- Review foreign-currency exposure, lease and purchase commitments, and the contingent milestone and royalty obligations under the University of Guelph license.